Anthracycline cardiotoxicity

Expert Opinion on Drug Safety

Volumn 11, Issue SUPPL. 1, 2012, Pages

  Menna, Pierantonio ^a   Gonzalez Paz, Odalys ^a   Chello, Massimo ^a   Covino, Elvio ^a   Salvatorelli, Emanuela ^a   Minotti, Giorgio ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Anthracyclines; Cardiotoxicity; Mechanisms; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARVEDILOL; CREMOPHOR; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DAUNORUBICINOL; DOCETAXEL; DOXORUBICIN; DOXORUBICINOL; ENALAPRIL; EPIRUBICIN; EPIRUBICINOL; IDARUBICIN; IDARUBICINOL; LAPATINIB; METOPROLOL; PACLITAXEL; PROBUCOL; RAZOXANE; REACTIVE OXYGEN METABOLITE; TRASTUZUMAB; VINCRISTINE;

BORDERLINE HYPERTENSION; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; COMORBIDITY; CONGESTIVE HEART FAILURE; DIASTOLIC DYSFUNCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DNA POLYMORPHISM; DRUG METABOLISM; DRUG POTENTIATION; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; KAPOSI SARCOMA; LIFESTYLE; LYMPHOMA; MULTIPLE CYCLE TREATMENT; OBESITY; OXIDATIVE STRESS; PHENOTYPE; PHYSICAL ACTIVITY; QT PROLONGATION; REVIEW; SIDE EFFECT;

ALCOHOLS; ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART DISEASES; HUMANS; LIFE STYLE; NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 84858693977     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.589834     Document Type: Review

References (87)

1. Swain SM, Whaley FS. Ewer, MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79 (Pubitemid 36605157)
2. Portera CC, Swain SM. The heart of the matter. J Clin Oncol 2007;25:3794-6 (Pubitemid 47477250)
3. Minotti G, Salvatorelli E, Menna P. Pharmacological foundations of Cardio-Oncology. J Pharmacol Exp Ther 2010;334:2-8
4. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82 (Pubitemid 44547808)
5. Mulrooney DA, Dover DC, Li S, et al. Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study. Cancer 2008;112:2071-9 (Pubitemid 351574084)
6. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007;25:3808-15 (Pubitemid 47477254)
7. Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-41 (Pubitemid 47494586)
8. Hudson MM, Rai SN, Nunez C, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007;25:3635-43 (Pubitemid 47372601)
9. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22:1864-71 (Pubitemid 41095177)
10. Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8:1039-58 (Pubitemid 46929299)
11. Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 2007;7:129-34 (Pubitemid 47339859)
12. Menna P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs. Chem Res Toxicol 2008;21:978-89
13. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229 (Pubitemid 38720829)
14. Hale SL, Shryock JC, Belardinelli L, et al. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol 2008;44:954-67
15. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007;99:206-14
16. Tokarska-Schlattner M, Lucchinetti E, Zaugg M, et al. Early effects of doxorubicin in perfused heart: transcriptional profiling reveals inhibition of cellular stress response genes. Am J Physiol 2010;298:1075-88
17. Danesi R, Fogli S, Gennari A, et al. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002;41:431-44 (Pubitemid 34753680)
18. Sissung TM, Gardner ER, Piekarz RL, et al. Impact of ABCB1 allelic variants on QTc interval prolongation. Clin Cancer Res 2011;17:937-46
19. Kang YJ, Chen Y, Epstein PN. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 1996;271:12610-16 (Pubitemid 26160936)
20. Yen HC, Oberley TD, Vichitbandha S, et al. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 1997;98:1253-60 (Pubitemid 26299939)
21. Kang YJ, Chen Y, Yu A, et al. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 1997;100:1501-6 (Pubitemid 27425776)
22. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-62 (Pubitemid 44855419)
23. Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol 2010;85:894-6
24. Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 2007;67:8839-46 (Pubitemid 47437460)
25. Martin E, Thougaard AV, Grauslund M, et al. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology 2009;255:72-9
26. Sterba M, Popelova O, Simunek T, et al. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. J Pharmacol Exp Ther 2006;319:1336-47
27. Popelova O, Sterba M, Simunek T, et al. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. J Pharmacol Exp Ther 2008;326:259-69 (Pubitemid 351872152)
28. Salvatorelli E, Menna P, Lusini M, et al. Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart. J Pharmacol Exp Ther 2009;329:175-84
29. Lebrecht D, Walker UA. Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 2007;7:108-13 (Pubitemid 47339856)
30. Menna P, Salvatorelli E, Gianni L, Minotti G. Anthracycline cardiotoxicity. Top Curr Chem 2008;283:21-44
31. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990;4:3076-86
32. Forrest GL, Gonzalez B, Tseng W, et al. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 2000;60:5158-64
33. Olson LE, Bedja D, Alvey SJ, et al. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 2003;63:6602-6 (Pubitemid 37336434)
34. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinine oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008;112:2789-95 (Pubitemid 351969225)
35. Gonzalez-Covarrubias V, Ghosh D, Lakhman SS, et al. A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity. Drug Metab Dispos 2007;35:973-80 (Pubitemid 46798608)
36. Ax W, Soldan M, Koch L, Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 2000;59:293-300 (Pubitemid 30001756)
37. Gonzalez B, Akman S, Doroshow J, et al. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells. Cancer Res 1995;55:4646-50
38. Salvatorelli E, Menna P, Cascegna S, et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther 2006;318:424-33
39. Salvatorelli E, Menna P, Gianni L, Minotti G. Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies. J Pharmacol Exp Ther 2007;320:790-800 (Pubitemid 46147961)
40. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337-50
41. van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010;12:CD005006
42. Blanco JG, Sun C, Chen L, et al. Anthracycline-related cardiomyopathy in childhood cancer survivors and association with polymorphisms in the carbonyl reductase genes: a Children's Oncology Group study. J Clin Oncol 2010;28(7S):A9512
43. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence finding study. J Clin Oncol 1995;13:2688-99
44. Perotti S, Cresta G, Grasselli G, et al. Cardiotoxic effects of anthracycline-taxane combinations. Expert Opin Drug Saf 2003;2:59-71
45. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21:968-75 (Pubitemid 46594123)
46. Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005;11:8715-21 (Pubitemid 43005921)
47. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13 (Pubitemid 40740554)
48. Gennari A, Salvadori B, Donati S, et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 1999;17:3596-602 (Pubitemid 29517932)
49. Pagani O, Sessa C, Nole F, et al. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann Oncol 2000;11:985-91
50. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007;25:3991-4008 (Pubitemid 47477279)
51. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92 (Pubitemid 32222155)
52. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol 2007;25:3859-65 (Pubitemid 47477261)
53. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51 (Pubitemid 47026733)
54. Gassmann M, Casagrand F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ERBB4 neuregulin receptor. Nature 1995;378:390-4
55. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995;378:386-90
56. Crone SA, Zhao YY, Fan L, et al. ERBB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-65 (Pubitemid 34546747)
57. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23:2900-2 (Pubitemid 46224107)
58. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006;24:4107-11
59. Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: Translating molecular mechanisms into preventative medicine. Mol Interv 2005;5:163-71 (Pubitemid 41018273)
60. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910-16
61. McArthur HL, Chia S. Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 2007;357:94-5
62. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:3525-33 (Pubitemid 47310891)
63. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 2007;116:954-60 (Pubitemid 47300920)
64. Beauclair S, Formento P, Fischel JL, et al. Role of the HER2 Ile655Val genetic polymorphism in tumorigenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol 2007;18:1335-41 (Pubitemid 47305006)
65. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-38 (Pubitemid 47073544)
66. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-Positive advanced breast cancer. N Engl J Med 2007;355:2733-43
67. Capri G, Chang J, Chen SC, et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010;21:474-80
68. von Minckwitz G, Eidtmann H, Loibl S, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011;22:301-6
69. Spector NL, Yarden Y, Smith B, et al. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci USA 2007;104:10607-12 (Pubitemid 47185712)
70. Azim H, Azim HA Jr, Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev 2009;35(5):633-8
71. Morris PG, Chen C, Steingart RM, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res 2011; Epub ahead of print
72. D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23:7135-42
73. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol 2002;20:1677-82 (Pubitemid 34260550)
74. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15:1318-32 (Pubitemid 27167363)
75. Alvarez JA, Scully RE, Miller TL, et al. Long-term effects of treatments for childhood cancers. Curr Opin Pediatr 2007;19:23-31 (Pubitemid 46114754)
76. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004;130:1-7 (Pubitemid 38161241)
77. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20:2895-903 (Pubitemid 34651519)
78. DeFeo-Jones D, Garsky VM, Wong BK, et al. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 2000;6:1248-52
79. Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002;20:1668-76 (Pubitemid 34260549)
80. Carver JR, Desai CJ. Cardiovascular toxicity of antitumor drugs: dimension of the problem in adult settings. In: Minotti G. editor, Cardiovascular toxicity of non cardiovascular drugs. Wiley, London; 2010. p. 127-99
81. Untch M, Eidtmann H, du Bois A, et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 2004;40:988-97 (Pubitemid 38496254)
82. Batist G. Cardiac safety of liposomal anthracyclines. Cardiovasc Toxicol 2007;7:72-4 (Pubitemid 47339870)
83. van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010;12:CD005006
84. Cortes J, Di Cosimo S, Climent MA, et al. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res 2009;15:307-14
85. Stickeler E, Klar M, Watermann D, et al. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Res Treat 2009;117:591-8
86. Gianni L, Valagussa P. Anthracyclines and early breast cancer: the end of an era? J Clin Oncol 2009;27:1155-7
87. Minotti G, Sarvazyan N. The anthracyclines: when good things go bad. Cardiovasc Toxicol 2007;7:53-5 (Pubitemid 47339866)